Equities analysts predict that Tandem Diabetes Care Inc (NASDAQ:TNDM) will post earnings per share of ($0.39) for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Tandem Diabetes Care’s earnings, with the highest EPS estimate coming in at ($0.36) and the lowest estimate coming in at ($0.44). Tandem Diabetes Care reported earnings of ($3.09) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 87.4%. The firm is scheduled to issue its next earnings results on Thursday, October 25th.

On average, analysts expect that Tandem Diabetes Care will report full year earnings of ($3.17) per share for the current financial year, with EPS estimates ranging from ($3.59) to ($2.81). For the next fiscal year, analysts forecast that the company will post earnings of ($0.90) per share, with EPS estimates ranging from ($1.25) to ($0.54). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that follow Tandem Diabetes Care.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its earnings results on Monday, July 30th. The medical device company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.82). The firm had revenue of $34.10 million during the quarter, compared to the consensus estimate of $29.68 million. The firm’s revenue for the quarter was up 60.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.44) earnings per share.

A number of brokerages have recently issued reports on TNDM. Dougherty & Co began coverage on Tandem Diabetes Care in a research report on Friday. They set a “buy” rating and a $45.00 target price on the stock. Bank of America raised Tandem Diabetes Care from an “underperform” rating to a “neutral” rating and set a $45.00 price target on the stock in a research report on Friday. BidaskClub raised Tandem Diabetes Care from a “buy” rating to a “strong-buy” rating in a research report on Thursday. Stifel Nicolaus began coverage on Tandem Diabetes Care in a research report on Wednesday. They set a “hold” rating and a $34.00 price target on the stock. Finally, Lake Street Capital upped their price target on Tandem Diabetes Care from $35.00 to $65.00 and gave the company a “buy” rating in a research report on Monday, August 20th. Three investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $30.85.

Shares of Tandem Diabetes Care stock traded down $0.24 on Wednesday, reaching $38.37. 4,577,361 shares of the company were exchanged, compared to its average volume of 3,054,667. The firm has a market capitalization of $2.02 billion, a PE ratio of -2.98 and a beta of 0.02. The company has a quick ratio of 2.43, a current ratio of 3.02 and a debt-to-equity ratio of 2.97. Tandem Diabetes Care has a fifty-two week low of $2.14 and a fifty-two week high of $40.04.

In other Tandem Diabetes Care news, Director Richard P. Valencia purchased 1,754 shares of the company’s stock in a transaction that occurred on Friday, August 3rd. The shares were purchased at an average cost of $28.50 per share, with a total value of $49,989.00. Following the completion of the transaction, the director now owns 1,754 shares of the company’s stock, valued at $49,989. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 9.30% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of TNDM. Wasatch Advisors Inc. grew its stake in Tandem Diabetes Care by 225.2% in the first quarter. Wasatch Advisors Inc. now owns 905,977 shares of the medical device company’s stock valued at $4,494,000 after purchasing an additional 627,410 shares in the last quarter. Frontier Capital Management Co. LLC boosted its stake in shares of Tandem Diabetes Care by 475.8% during the 1st quarter. Frontier Capital Management Co. LLC now owns 2,720,937 shares of the medical device company’s stock worth $13,496,000 after acquiring an additional 2,248,382 shares in the last quarter. First Mercantile Trust Co. boosted its stake in shares of Tandem Diabetes Care by 1,051.3% during the 1st quarter. First Mercantile Trust Co. now owns 44,866 shares of the medical device company’s stock worth $223,000 after acquiring an additional 40,969 shares in the last quarter. Northern Trust Corp bought a new stake in shares of Tandem Diabetes Care during the 1st quarter worth about $415,000. Finally, Cetera Advisor Networks LLC bought a new stake in shares of Tandem Diabetes Care during the 1st quarter worth about $117,000. Hedge funds and other institutional investors own 59.48% of the company’s stock.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Further Reading: Stock Symbols Definition, Examples, Lookup

Get a free copy of the Zacks research report on Tandem Diabetes Care (TNDM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.